[1]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1-3.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(09):1-3.
点击复制

扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年09期
页码:
1-3
栏目:
出版日期:
2013-09-15

文章信息/Info

Title:
Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer
文章编号:
1004-6852(2013)09-0001-03
作者:
李树建
广元市第四人民医院外科，四川 广元 628000
Author(s):
LI Shujian
Surgical Department of Guangyuan Municipal The 4th People's Hospital, Guangyuan 628000, China
关键词:
乳腺癌; 扶正祛积汤; CEF; 晚期
Keywords:
mammary cancer;  FuZheng QuJiTang;  CEF;  advanced
分类号:
R737.9
文献标志码:
A
摘要:
目的：观察扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌的临床疗效。方法：将80例晚期乳腺癌患者随机分为观察组、对照组各40例。2组均给予CEF化疗方案，观察组同时给予扶正祛积方，1剂/d，水煎分服。2组均以3周为1个周期，常规治疗4个周期。结果：总有效率观察组为92.50%，对照组为75.00%，2组比较差异有统计学意义（P＜0.05）。2组生理机能、躯体疾病、一般健康状况、精力、精神健康等生活质量评价标准治疗后较治疗前明显改善(P＜0.05)；观察组改善较对照组明显（P＜0.05）。细胞免疫功能指标（包括外周血CD+4，CD+8和CD+4/CD+8百分比）、体液免疫功能指标（包括血清免疫球蛋白IgG,IgA和IgM）2组治疗后均有明显改善(P＜0.05)；且观察组改善较对照组明显(P＜0.05)。结论：扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌临床疗效较好，可明显改善患者生活质量，提高患者免疫功能。
Abstract:
Objective: To observe curative effects of FuZheng QuJiTang and CEF chemotherapy in treating advanced mammary cancer. Method: All 80 patients were separated into the observation group and the control group. Both group accepted CEF chemotherapy, the observation group took FuZheng QuJiTang, one dose per day, water decocted. Three weeks were one course of treatment and both groups were treated for four consecutive courses of treatment. Result: Total effective rate of the observation group was 92.50%, higher than 75.00% of the control group, the difference between both groups had statistical meaning(P＜0.05). The indexes of both groups were improved after treating which included physiological function, somatic diseases, general health, energy and emotional health(P＜0.05); the observation group was improved more significantly(P＜0.05). Cellular immune function (including peripheral blood CD+4, CD+8 and CD+4/ CD+8 percentage) and humoral immune function (including serum immune globulin IgG, IgA and IgM) were improved more notably after treating in both groups (P＜0.05); the improvement of the observation group was more significant than that of the control group (P＜0.05). Conclusion: FuZheng QuJiTang and CEF chemotherapy are effective in treating advanced mammary cancer, it could improve life quality of the patients obviously and immune function of the patients.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(09):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(09):7.
[9]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(09):114.
[10]王泽芬.集束护理干预策略对乳腺癌保乳术后放化疗患者的影响[J].西部中医药,2015,28(04):137.

备注/Memo

备注/Memo:
收稿日期：2013-03-25 作者简介：李树建(1970—)，男，主治医师。研究方向：普外科常见病的中西医诊治。
更新日期/Last Update: 2013-09-15